Cencora Beat the Number. The Peer Comparison Says It Still Hasn't Earned Its Premium.

Cencora (COR) reported earnings per share of $4.48 for the third quarter of fiscal 2026, beating the consensus estimate of $4.36 by roughly 2.75%. The beat was real. It also wasn't the whole story.

The sequential picture is the part that doesn't make the headline. Second-quarter adjusted EPS was $4.75. Earnings fell roughly 6% from one quarter to the next. Revenue consensus was pegged at approximately $84.9 billion, implying roughly 5.2% year-over-year growth - slower than the 8.7% the company posted in the same quarter a year ago. The deceleration isn't a Cencora-specific failure; it's a structural feature of a sector where manufacturer list-price reductions, branded-to-biosimilar conversions, and moderating GLP-1 growth weigh on every distributor's top line. But if you're paying a premium for Cencora's specialty pharmaceutical focus, you'd want to see that advantage grow, not shrink.

So let's check the comparison set.

Valuation: the premium is real and the math isn't on its side

Cencora trades at 23.4 times trailing earnings. McKesson (MCK), the largest of the three major U.S. pharmaceutical distributors, trades at 20.4x. Cardinal Health (CAH) is at 35.2x, but that's a special situation - CAH is still working through legacy issues and the market is rewarding a deeper turnaround play, not a cleaner business. The meaningful comparison is Cencora versus McKesson.

The gap widens on EV/EBITDA (enterprise value relative to earnings before interest, taxes, depreciation, and amortization - a cash-earnings proxy that strips out capital structure differences). Cencora sits at 25.2x. McKesson is at 14.4x. That is a 75% premium on a metric that measures how much you're paying for each dollar of operating cash earnings. In a thin-margin distribution business, that is a lot of premium to justify.

Growth: the premium should be doing more work

Here's where the story gets harder. Revenue growth year-over-year is 5.9% for Cencora versus 12.4% for McKesson and 12.8% for Cardinal. The specialty pharmaceutical edge - Cencora's stated competitive moat - has not translated into faster revenue growth versus the general distribution set. Gross profit growth is better at 19.0% versus McKesson's 9.2%, which supports the thesis that the specialty mix is higher-margin. But gross margin itself is 3.8%, only marginally above McKesson's 3.6%.

The free cash flow number is the one that matters most for the valuation premium. Cencora's free cash flow is down 56.4% year-over-year. McKesson's is up 3.5%. Cardinal's is up 78.9%. In a business where operating margins are measured in single-digit percentages and every basis point of gross margin matters, a free cash flow collapse of that magnitude deserves an explanation. Whether it's working capital, inventory build, or timing, the direction is wrong for a stock trading at 25.2x EV/EBITDA.

The PEG ratios look attractive on paper - Cencora at 0.46, McKesson at 0.42 - but PEG is a lagging indicator built on trailing data. It tells you what growth has already happened, not what's coming. The forward PE of 23.6x for Cencora versus McKesson's 31.0x looks favorable, but forward estimates for McKesson are based on a smaller earnings base and a more cyclical revenue pattern. The comparison set doesn't crown a clear winner.

Safety: high leverage, manageable for now

Cencora carries $78.1 billion in total debt against $3.6 billion in equity, a debt-to-equity ratio of 345%. That sounds alarming until you remember that pharmaceutical distributors run extremely tight balance sheets with enormous inventory turnover and minimal asset bases. Net debt of $10.2 billion is the more relevant figure. The quick ratio (current assets minus inventory, divided by current liabilities) sits at 59%, and the current ratio is 94.7%. Both are below 1.0, meaning Cencora relies on inventory liquidation to meet near-term obligations - which it can do, but it leaves no cushion if supply chain dynamics shift.

ROIC (return on invested capital) of 14.7% is solid. It tells you the business earns above its cost of capital on the debt it carries. But ROE of 115.6% is a leverage artifact, not a profitability signal - when equity is only $3.6 billion on a $59.6 billion market cap, the ROE number measures leverage, not excellence.

Momentum: the stock says it doesn't believe the premium

Cencora's shares are at $306.28, roughly 9.3% down year-to-date and 14.9% below where they were four months ago. The stock sits below its 200-day moving average of $324.44. The 50-day moving average is at $290.14, which means the stock is in a squeeze between its medium-term uptrend and long-term downtrend. The RSI (Relative Strength Index, a momentum oscillator where readings above 70 suggest overbought conditions and below 30 suggest oversold) is at 53.5 - neutral. The MACD (Moving Average Convergence Divergence, a trend-following momentum indicator) is positive at 5.51, suggesting short-term upward pressure. But a stock that has lost ground for three months while beating quarterly estimates is telling you that the market has questions the earnings print doesn't answer.

What the factor stack says

The valuation factor is a mixed signal. Cencora's EV/EBITDA of 25.2x is the highest of the three distributors. The trailing PE of 23.4x is above McKesson but below Cardinal. In a sector where gross margins hover near 4% and operating margins near 1%, valuation spreads of this size matter.

Growth is the weak link. Revenue growth of 5.9% is the lowest of the set. Free cash flow declining 56% is the weakest by far. The specialty focus hasn't delivered faster top-line growth yet, even if gross profit growth of 19.0% shows some margin improvement.

Profitability quality is adequate. ROIC of 14.7% is the best of the three on an efficiency basis (McKesson's 105.9% ROIC is distorted by a tiny equity base). Gross margin growth is the strongest. But absolute margins are still thin.

Safety is thin. The balance sheet is highly leveraged, liquidity ratios are below 1.0, and the business depends on continuous inventory turnover. It's a structure that works in normal conditions and becomes fragile when they don't.

Momentum is neutral-to-negative. The stock is below its 200-day average, down 15% over 120 days, with no clear directional signal.

Portfolio placement and what changes the view

Cencora doesn't currently have a portfolio role that justifies its valuation premium. It's too expensive for a pure value play - McKesson delivers faster growth at a lower multiple. It's not growing fast enough to serve as a growth sleeve anchor. It's too leveraged for a barbell safety position. The stock sits in the gap between categories, which is exactly where the market has been punishing it over the past quarter.

The thesis that would make Cencora compelling is straightforward: specialty pharmaceuticals continue to represent an outsized and growing share of the revenue mix, gross profit growth outpaces revenue growth for enough consecutive quarters to prove the margin expansion thesis, and free cash flow stabilizes or rebounds. If those three things happen, the 25.2x EV/EBITDA starts to look like patience, not overpayment.

The trigger that would change the view most quickly is the free cash flow number. A quarter of FCF recovery would tell you the decline is cyclical. Another quarter of decline would tell you the structural pricing pressure is eating into cash generation faster than the specialty mix is compensating. That's the data point to watch in the next report.

AInvest's aggregate signal labels Cencora a Buy, with a fundamental rating of 7.97 out of 10. That's a supportive cross-check, but it's an opaque score - the factor breakdown above is where the actual evidence lives.

Cencora beat the number. The peer comparison says the premium it commands hasn't been earned yet. That doesn't mean the stock is wrong - it means the specialty story has to deliver more proof before the multiple looks justified.